Stephen P. Hunger, MD

faculty photo
Professor of Pediatrics
Attending Physician, Children's Hospital of Philadelphia, Division of Oncology
Chief, Division of Oncology, Children's Hospital of Philadelphia, Department of Pediatrics
Director, Center for Childhood Cancer Research, Children's Hospital of Philadelphia
Associate Director for Pediatric Research, Abramson Cancer Center
Member, Executive Committee, Abramson Cancer Center
Department: Pediatrics

Contact information
Division of Oncology
Colket Translational Research
Room 3060
3501 Civic Center Blvd
Philadelphia, PA 19104
Office: 267-425-0197
BS (Applied Biology)
Massachusetts Institute of Technology, 1981.
University of Connecticut School of Medicine, 1985.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Burke MJ, Devidas M, Chen Z, Salzer WL, Raetz EA, Rabin KR, Heerema NA, Carroll AJ, Gastier-Foster JM, Borowitz MJ, Wood BL, Winick NJ, Carroll WL, Hunger SP, Loh ML, Larsen EC. : Outcome in Adolescent and Young Adult Patients (16-30 years) Compared to Younger Patients Treated for High-risk B-lymphoblastic Leukemia. Report from Children’s Oncology Group Study AALL0232. Leukemia 36(648-655), Nov 2022 Notes: [Epub 2021 Nov 1]

Hastings C, Chen Y, DevidasM, Ritchey AK, Winick NJ, Carroll WL, Hunger SP, Wood BL, Marcus RB, Barredo JC. : Late isolated central nervous system relapse in childhood B-cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced-dose cranial radiation: A report from the Children’s Oncology Group study AALL02P2. Pediatric Blood and Cancer 68: e29256, July 2022 Notes: [Epub 2021 Jul 24]

Zhao X, Qian M, Goodings C, Zhang Y, Yang W, Wang P, Xu B, Tian C, Pui C-H, Hunger SP, Raetz EA, Devidas M, Relling MV, Loh ML, Savic D, Li C, Yang JJ. : Molecular Mechanisms of ARID5B-mediated Genetic Susceptibility to acute lymphoblastic leukemia. Journal of the National Cancer Institute May 2022 Notes: [Online ahead of print]

Rodwin RL, Kairalla JA, Hibbitts E, Devidas M, Whitley MK, Mohrmann CE, Schore RJ, Raetz E, Winick NJ, Hunger SP, Loh ML, Hockenberry MJ, Angiolillo AL, Ness KK, Kadan-Lottick NS. : Persistence of chemotherapy-induced peripheral neuropathy despite vincristine reduction in childhood B-acute lymphoblastic leukemia: A report from Children’s Oncology Group AALL0932. Journal of the National Cancer Institute May 2022 Notes: [Online ahead of print]

Bomken S, Enshaei A, Schwalbe EC, Mikulasova A, Dai Y, Zaka M, Fung KTM, Bashton M, Lim H, Jones L, Karataraki N, Winterman E, Ashby C, Attarbaschi A, Bertrand Y, Bradtke J, Buldini B, Burke GAA, Cazzaniga G, Göhring G, de Groot-Kruseman HA, Haferlach C, Lo Nigro L, Parihar M, Plesa A, Seaford E, Sonneveld E, Strehl S, van der Velden VHJ, Rand V, Hunger SP, Harrison CJ, Bacon CM, van Delft FW, Loh ML, Moppett J, Vormoor J, Walker BA, Moorman AV, Russell LJ. : Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement. Haematoligica Apr 2022 Notes: [Online ahead of print]

Pritchard-Jones K, Challinor JM, Hunger SP, Sung L, Davidson A, Morrissey LK, Khan MS, Dalvi RB, Sullivan MJ, Hessissen L, Chantada GL, Kearns P, Frazier AL, Wollaert S, Laub T. : SIOP Strategy 2021–2025: Cure For More, Care For All. Pediatric Blood and Cancer 69: 29577, 2022 Notes: [Epub 2022 Feb 15.]

Guest E, Kairalla JA, Hilden JM. Dreywe ZE, Carroll AJ Heerema NA, Wang CY, Devidas M, Gore L, Salzer WL, Winick NJ, Carroll WL, Raetz EA, Borowitz M, Loh ML, Hunger SP, Brown PA. : Outstanding outcomes in infants with KMT2A-germline acute lymphoblastic leukemia treated with chemotherapy alone: Results of the Children’s Oncology Group AALL0631 trial. Haematologica 107: 1205 - 1208, 2022.

Kimura S, Montefiori L, Iacobucci I, Zhao Y, Gao Q, Paietta EM, Haferlach C, Laird AD, Mead P, Gu Z, Stock W, Litzow M, Rowe JM, Luger SM, Hunger SP, Ryland G, Schmidt BM, Ekert PG, Oshlack A, Grimmond AM, Rehn J, Breen J, Yeung DT, White DL, Aldoss I, Jabbour EJ, Pui CH, Meggendorfer M, Wallter W, Kern W, Haferlach T, Brady SW, Zhang J, Roberts KG, Blomberry P, Mullighan CG. : Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high risk B-progenitor acute lymphoblastic leukemia. Blood 139: 3519 - 3531, 2022 Notes: [Epub Feb 22]

Teachey DT, Devidas M, Wood BL, Chen Z, Hayashi RJ, Hermiston ML, Annett RD, Archer JH, Asselin BL, August KJ, Cho SY, Dunsmore KP, Fisher BT, Freedman JL, MD, Galardy PJ, Harker-Murray P, Horton TM, Jaju AI, Lam A, Messinger YH, Miles RR, Okada M, Patel SI, Schafer ES, Schechter T, Singh N, Steele AC, Sulis ML, Vargas SL, Winter SS, Wood C, Zweider-McKay P, Bollard CM, Loh ML*, Hunger SP*, Raetz EA*. *MLL, SPH, and EAR contributed equally as senior authors. : Children’s Oncology Group Trial AALL1231: A Phase 3 Clinical Trial Testing Bortezomib in Newly Diagnosed T-cell Acute Lymphoblastic Leukemia and Lymphoma. Journal of Clinical Oncology 40: 2106-2118, 2022 Notes: [Epub 2022 Mar 10]

Leahy AB, Devine KJ, Li Y, Liu H, Myers R, DiNofia AM, Wray L, Rheingold SR, Callahan C, Baniewicz D, Patino MM, Newman H, Hunger SP, Grupp SA, Barrett DM, Maude SL. : Impact of High-Risk Cytogenetics on Outcomes for Children and Young Adults Receiving CD19-Directed CAR T Cell Therapy. Blood 7(139): 2173-2185, 2022 Notes: [Epub 2021 Dec 27]

back to top
Last updated: 08/15/2022
The Trustees of the University of Pennsylvania